Metastasis-directed radiation therapy plus hormone therapy improves progression-free survival for men with advanced prostate cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were published today in JAMA Oncology and were first presented at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting...
MD Anderson’s Guillermina Lozano receives AAMC Award for Distinguished Research in the Biomedical Sciences
In recognition of her trailblazing work uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of...
Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe...
Some breast cancer patients with high responses to chemotherapy may not need surgery
Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery and receive standard radiation treatment with a low chance of disease recurrence, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
The Phase II trial results, published today in Lancet Oncology, evaluated the likelihood of breast cancer returning...
Response-adapted ultra-low dose radiation achieves complete response in 90% of patients with orbital indolent B-cell lymphomas
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center...
Allison Institute establishes internal advisory council of MD Anderson experts
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory...
MD Anderson and WHO establish new international collaboration to reduce women’s cancers
The University of Texas MD Anderson Cancer Center and World Health Organization (WHO) today announced a formal agreement to establish a new...
MD Anderson Research Highlights for October 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson hosts Leading Edge of Cancer Research Symposium
The University of Texas MD Anderson Cancer Center will host its virtual Leading Edge of Cancer Research Symposium from November 17-18, 2022...
Lung, breast and colorectal cancer tackled in latest Texas computational oncology collaboration
Three new cancer research projects have been chosen to receive seed funding as part of the program in Oncological Data and Computational Science...
MD Anderson and ARTIDIS announce strategic alliance to advance nanomechanical technology platform for optimizing cancer treatment
The University of Texas MD Anderson Cancer Center and ARTIDIS AG today announced a strategic alliance to investigate ARTIDIS technology as...